MedTrace Logo

TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection

NCT03964493 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2023-12-01

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate safety, tolerability, pharmacokinetic characteristics and efficacy of TNP-2092 in adults with ABSSSI suspected or confirmed to be caused by gram-positive pathogens.

Conditions

  • Skin and Subcutaneous Tissue Bacterial Infections
  • Gram-Positive Bacterial Infections

Interventions

DRUG

TNP-2092

TNP-2092 100mg/vial

DRUG

Vancomycin

Vancomycin 1g/vial

Sponsors & Collaborators

  • TenNor Therapeutics Limited

    lead INDUSTRY

Principal Investigators

  • TenNor Clinical Trials · TenNor

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-20
Primary Completion
2020-09-28
Completion
2020-09-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03964493 on ClinicalTrials.gov